Celltrion - Public Comps and Valuation Multiples

Celltrion Overview

About Celltrion

Founded in 2002 in South Korea, Celltrion is one of the largest biosimilar manufacturers around the world. Biosimilar drug sales accounted for 87% of its total revenue in 2024. Europe is the largest market for its biosimilar drug sales, contributing more than 47% of its total revenue, followed by 37% from the North America region and 16% from emerging markets. Besides biosimilar manufacturing, Celltrion entered the contract manufacturing business in 2024.

Founded

1991

HQ

Employees

n/a

Website

celltrion.com

Sectors

Biopharmaceuticals
BioTech

Financials

LTM Revenue $2.9B

LTM EBITDA $985M

EV

$28.7B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Celltrion Financials

As of September 2025, Celltrion reported last 12-month revenue of $2.9B and EBITDA of $985M.

In the same period, Celltrion generated $1.6B in LTM gross profit and $533M in net income.

See Celltrion valuation multiples based on analyst estimates

Celltrion P&L

In the most recent fiscal year, Celltrion reported revenue of $2.5B and EBITDA of $749M.

Celltrion expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Celltrion valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$2.9B	XXX	$2.5B	XXX	XXX	XXX
Gross Profit	$1.6B	XXX	$1.2B	XXX	XXX	XXX
Gross Margin	56%	XXX	47%	XXX	XXX	XXX
EBITDA	$985M	XXX	$749M	XXX	XXX	XXX
EBITDA Margin	34%	XXX	30%	XXX	XXX	XXX
EBIT	$723M	XXX	$344M	XXX	XXX	XXX
EBIT Margin	25%	XXX	14%	XXX	XXX	XXX
Net Profit	$533M	XXX	$296M	XXX	XXX	XXX
Net Margin	19%	XXX	12%	XXX	XXX	XXX
Net Debt	XXX	XXX	$815M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Celltrion including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $2.9B. EBITDA for the last twelve months was $985M. In the most recent fiscal year, Celltrion achieved $2.5B in revenue and $749M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$2.9B	Analyst estimates available to subscribers	$2.5B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$1.6B	Analyst estimates available to subscribers	$1.2B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	56.1% gross margin	Analyst estimates available to subscribers	47.3% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$985M	Analyst estimates available to subscribers	$749M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	34.3% EBITDA margin	Analyst estimates available to subscribers	30.1% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$723M	Analyst estimates available to subscribers	$344M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	25.2% EBIT margin	Analyst estimates available to subscribers	13.8% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$533M	Analyst estimates available to subscribers	$296M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	18.6% net profit margin	Analyst estimates available to subscribers	11.9% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$815M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Celltrion

This financial data table provides comprehensive performance metrics for Celltrion, a company based in South Korea. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Celltrion generated $2.9B in revenue over the last twelve months.
The company achieved $985M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $1.6B.
Net income over the last twelve months reached $533M.

Fiscal Year Performance

In the most recent fiscal year, Celltrion reported $2.5B in total revenue.
Fiscal year EBITDA was $749M.
The company maintained a gross profit margin of 47.3% in the most recent fiscal year.
EBITDA margin for the fiscal year was 30.1%.
Net profit margin reached 11.9% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Celltrion. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Celltrion Stock Performance

Celltrion has current market cap of KRW 39.36T (or $27.5B), and EV of KRW 41.08T (or $28.7B).

Market Cap Evolution

Celltrion Stock Data

As of October 17, 2025, Celltrion's stock price is KRW 175000 (or $122).

See Celltrion trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$28.7B	$27.5B	XXX	XXX	XXX	XXX	$2.37

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Celltrion Valuation Multiples

Celltrion's trades at 11.5x EV/Revenue multiple, and 38.4x EV/EBITDA.

See valuation multiples for Celltrion and 15K+ public comps

Celltrion Financial Valuation Multiples

As of October 17, 2025, Celltrion has market cap of $27.5B and EV of $28.7B.

Equity research analysts estimate Celltrion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Celltrion has a P/E ratio of 51.7x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$27.5B	XXX	$27.5B	XXX	XXX	XXX
EV (current)	$28.7B	XXX	$28.7B	XXX	XXX	XXX
EV/Revenue	10.0x	XXX	11.5x	XXX	XXX	XXX
EV/EBITDA	29.2x	XXX	38.4x	XXX	XXX	XXX
EV/EBIT	39.7x	XXX	83.5x	XXX	XXX	XXX
EV/Gross Profit	17.8x	XXX	n/a	XXX	XXX	XXX
P/E	51.7x	XXX	93.1x	XXX	XXX	XXX
EV/FCF	87.3x	XXX	72.3x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Celltrion Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Celltrion Margins & Growth Rates

Celltrion's last 12 month revenue growth is 18%

Celltrion's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Celltrion's rule of 40 is 61% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Celltrion's rule of X is 80% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Celltrion and other 15K+ public comps

Celltrion Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	18%	XXX	19%	XXX	XXX	XXX
EBITDA Margin	34%	XXX	30%	XXX	XXX	XXX
EBITDA Growth	34%	XXX	29%	XXX	XXX	XXX
Rule of 40	61%	XXX	48%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	80%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	11%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	6%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	33%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial